مباشر

FierceBiotechRoche nabs European approval for second Eli Lilly-partnered Alzheimer’s test FierceBiotechBayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug BioPharma DiveA year after Vertex’s big launch, pain drug research faces a pivotal moment Endpoints NewsFlagship startup Serif says it has solved non-viral gene therapy in monkeys FierceBiotechBlood-based approach could detect early heart, kidney disease, study finds Endpoints NewsBristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B AgilentAgilent expands collaboration with C-CAMP to scale access to advanced life sciences analytics - BioSpectrum India FierceBiotechEnterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled LabiotechThe real reason CGT programs struggle to scale FierceBiotechBristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed eLifeScience under threat around the world eLifeFunctional imaging of nine distinct neuronal populations under a miniscope in freely behaving animals

Labiotech ١٢ مايو ٢٠٢٦

The real reason CGT programs struggle to scale

Learn how cryopreservation improves scalability and helps CGT programs move from early development to commercial manufacturing. The post The real reason CGT pro...

Learn how cryopreservation improves scalability and helps CGT programs move from early development to commercial manufacturing. The post The real reason CGT programs struggle to scale appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.